Market Capitalization

As BNB Plus Corp. falls from Nasdaq to the over-the-counter markets, its hybrid crypto-biotech model is under intense scrutiny. What does this mean for investors?

Chesapeake Utilities is doubling down on the Sunshine State with a massive natural gas pipeline. But is this $1.2 billion project a masterstroke or a risky gamble?

Amid key technical wins like piloted transition, Vertical Aerospace delays its eVTOL certification, a move reflecting an industry-wide reality check.

With Aon's Q2 results imminent, investors are watching key metrics, strategic moves, and how the firm navigates a complex global risk landscape.

Jiuzi Holdings touts a $1M profit from a new AI deal, but with an unnamed partner and mounting risks, is this a strategic pivot or a desperate gamble?

A mining firm just secured a key gene therapy patent for ALS. Timothy Bell dissects the audacious strategy of funding cutting-edge biotech with Greenland's mineral wealth.

The Chinese battery firm secures vital funds, but a plunging stock price and fierce competition reveal the high stakes of its survival strategy.

A new report reveals a massive surge in securities litigation, with alleged losses hitting $722 billion. What are the invisible risks threatening corporate giants?

Beyond just a new logo, Chicago Rivet & Machine Co.'s rebrand signals a strategic shift from parts supplier to a systems expert for the next century.

Serina Therapeutics' Parkinson's drug SER-252 advances, but the real story is its POZ Platform, a technology that could reshape drug delivery.

Vera Therapeutics just secured its first drug approval. Now, it's bringing in a regulatory heavyweight. We deconstruct the strategy behind the move.

SCP Standard Capital appoints Fabian Becker as CEO, solidifying its pivot from media to investment. Stephanie Schettler-Köhler's move to COO ensures stability.

Monster's 2-for-1 split isn't just a technicality. It's a signal of confidence backed by record sales, diversification, and a strategy to fuel growth.

Wrap Technologies pivots into high-tech defense, securing exclusive rights to an Israeli AI that detects 'silent' drones, a game-changer for public safety.

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

CDT Environmental regained Nasdaq compliance after a reverse stock split, but a look under the hood reveals financial strains and the persistent regulatory risks facing Chinese firms.

A Malaysian hotpot chain lands a massive data center deal, but with no tech experience and a plunging stock price, is this a brilliant pivot or a desperate gamble?

A Nevada geothermal utility plans a $40M solar investment to power critical mineral processing. It's a model for a green supply chain, if it survives the fine print.